
Peter Higgins
Director, T32 Digestive Disease Clinical Research Program · University of Michigan
Credentials: · · · · · ·
History
PresentT32 Digestive Disease Clinical Research Program · University of Michigan
Present
Present
- 2001–2004
- 1998–2001
Accelerate your career. Advance world health.


Research
Gut · 2012 · 1,277 citations
Epidemiology of constipation in North America: a systematic review
Systematic review or meta-analysis · The American Journal of Gastroenterology · 2004 · First of 2 authors · 711 citations
Review · Nature reviews. Cancer · 2005 · 678 citations

82 papers · 27 as a resident

56 papers · 6 as a fellow

47 papers · 15 as a fellow

35 papers · 2 as a fellow
- SG
28 papers · 10 as a resident

24 papers

20 papers
- KR
19 papers
Grants
- 2020–2030
Measuring Molecular and Mechanical Outcomes of Endoscopic Dilation of Fibrotic Strictures
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $3.3M · University of Michigan at Ann Arbor
- 2003–2028
Clinical Research in Digestive Diseases (CRDD) Training Program
National Institute of Diabetes and Digestive and Kidney Diseases · T32
Contact PI · $1.7M · University of Michigan at Ann Arbor
- 2018–2024
Inhibiting Bcl-2-Regulated Intestinal Fibrosis in Models of Crohn’s Disease
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $2.3M · University of Michigan at Ann Arbor
- 2016–2022
Nonlinear Ultrasound: An Imaging Biomarker of Intestinal Fibrosis in Crohn's Disease
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $2.4M · University of Michigan at Ann Arbor
Clinical trials
- 2021–2023
Microbiome Modification to Enhance Stelara Response in Crohn's Disease
Principal investigator · Withdrawn
University of Michigan
- 2019–2020
Principal investigator · Completed
University of Michigan
- 2015–2016
Trial of High Dose Vitamin D in Patient's With Crohn's Disease
Principal investigator · Terminated · Phase 4
University of Michigan
- 2013–2016
Calprotectin-Directed Humira® Maintenance Therapy (CADHUM)
Principal investigator · Withdrawn · Phase 3
Peter Higgins


